NCT04724343

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.

Effect of GnRH Agonist (Long Protocol) vs GnRH Antagonist (Flexible Protocol) on IVF/ICSI Outcomes.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Damascus University · Academic / Other
• Sex: Female
• Age: 18 Years – 39 Years
• Healthy volunteers: Not accepted

Summary

The aim of this prospective, non-randomised, open-label, clinical trial is to compare the effects of two pituitary suppression regimens; GnRH Agonist-Long Protocol and GnRH Antagonist-Flexible Protocol on clinical and embryological IVF/ICSI outcomes, and on the follicular fluid levels of Placental Growth Factor (PlGF); which is known for his pivotal role in the regulation of ovulation, embryo development, and implantation.

Conditions

• In Vitro Fertilization
• Intracytoplasmic Sperm Injection
• Infertility

Interventions

Type	Name	Description
DRUG	Triptorelin acetate	0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
DRUG	Cetrorelix	0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
DRUG	recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin	Dosage adjustment according to the ovarian response.
DRUG	Human Chorionic Gonadotropin (hCG)	Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.

Timeline

• Start date: 2019-12-22
• Primary completion: 2022-01-01
• Completion: 2022-07-05
• First posted: 2021-01-26
• Last updated: 2023-10-24

Locations

1 site across 1 country: Syria